MediWound (NASDAQ:MDWD – Get Free Report) is expected to be issuing its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect MediWound to announce earnings of ($0.7067) per share and revenue of $6.73 million for the quarter. Parties can check the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 12, 2026 at 8:30 AM ET.
MediWound (NASDAQ:MDWD – Get Free Report) last announced its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.77) EPS for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.01). MediWound had a negative net margin of 170.10% and a negative return on equity of 47.24%. The business had revenue of $3.09 million for the quarter, compared to the consensus estimate of $2.59 million. On average, analysts expect MediWound to post ($2.37) EPS for the current fiscal year and ($2.30) EPS for the next fiscal year.
MediWound Stock Up 6.0%
Shares of NASDAQ MDWD opened at $14.20 on Thursday. MediWound has a 52 week low of $11.80 and a 52 week high of $19.70. The company has a market cap of $182.47 million, a P/E ratio of -7.89 and a beta of 0.07. The business has a 50-day simple moving average of $13.09 and a two-hundred day simple moving average of $15.18.
Analyst Ratings Changes
Several research firms have commented on MDWD. Wall Street Zen raised shares of MediWound from a “strong sell” rating to a “sell” rating in a report on Saturday, September 26th. TD Cowen reaffirmed a “buy” rating on shares of MediWound in a research note on Thursday, September 24th. Alliance Global Partners reaffirmed a “buy” rating on shares of MediWound in a research report on Wednesday, September 16th. Oppenheimer reaffirmed an “outperform” rating and issued a $30.00 target price (down from $32.00) on shares of MediWound in a report on Friday, August 14th. Finally, Weiss Ratings downgraded shares of MediWound from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, September 8th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $33.00.
Check Out Our Latest Analysis on MDWD
Insider Activity
In other news, COO Shmuel Hess sold 3,958 shares of the firm’s stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $12.92, for a total transaction of $51,137.36. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 9.20% of the stock is owned by corporate insiders.
About MediWound
MediWound Ltd. (NASDAQ: MDWD) is a commercial-stage biotechnology company focused on developing and marketing innovative enzymatic therapies for complex wounds. The company’s products are designed to support the removal of damaged tissue and improve wound management, with an emphasis on severe burns and hard-to-heal chronic wounds.
MediWound’s lead product, NexoBrid, is a bromelain-based topical biological product used for the enzymatic removal of eschar, or dead tissue, from deep partial-thickness and full-thickness thermal burns.
See Also
- Five stocks we like better than MediWound
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for MediWound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound and related companies with MarketBeat.com's FREE daily email newsletter.
